CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Which Bond Fund Tax Efficiency Metrics To Use covers essential metrics like after-tax yield and tax-cost ratios, guiding retirees to smarter fund choices.
26,614 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Urban air mobility could redefine city travel, and Archer Aviation sits at the center of that promise. This guide bre...
What if the way we speak about money matters as much as the numbers we report? This finance-focused piece uses Christ...
Investors are watching Nomad Foods navigate a tough year. While the stock has fallen, there are hidden strengths and ...
Markets react after macquarie downgrades paypal cost-saving plan, citing a back-loaded path to benefits. Investors fo...
A tech leader argues AI will not replace workers, sparking a debate as employers weigh productivity gains against fea...
A CNBC analyst contends the FedEx selloff reflects misinterpretation of the income statement, not a collapse in deman...
A new industry view reframes AI as a productivity boost that reshapes tasks, not a job killer, while Gen Z markets fi...
CoreWeave unleashed resilient US-scale growth with a massive backlog, while Nebius posted stronger margins on a small...
Circle stock surged after first-quarter results beat expectations and a fresh Arc funding round. This Morning Minute ...
Ferrari delivered a quarter that topped estimates, yet the stock moved lower. This piece deciphers what drove the bea...
Two giants. One decision. This pipeline stock face-off: enbridge breaks down which energy infrastructure stock fits a...